An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma

Inclusion Criteria:

- Subject has completed a prior ABT-199 study (and had met the criteria for a diagnosis
of NHL and all other eligibility criteria for the previous study) and the investigator
believes that treatment with ABT-199 is in the best interest of the subject.

Exclusion Criteria:

- Subject discontinued ABT-199 administration before completing the prior study (due to
disease progression, toxicity, withdrawn consent, other).

- Subject has any medical condition that in the opinion of the investigator places the
subject at an unacceptably high risk for toxicities.

- Subject has not recovered to ≤ Grade 2 clinically significant adverse
effect(s)/toxicity(ies) of previous therapy.

- Subject has been diagnosed with Post-Transplant Lymphoproliferative Disease (PTLD),
Burkitt's lymphoma, Burkitt-like lymphoma, lymphoblastic lymphoma/leukemia, chronic
lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or mantle cell lymphoma
(MCL).